| abstract |
Modified androgen receptor polypeptides that exhibit resistance to inhibition by androgen receptor inhibitors are described herein. Compositions, formulations and kits comprising modified androgen receptor polypeptides, and methods of using modified androgen receptor polypeptides are described herein. Methods of using modified androgen receptor polypeptides as screening agents for the identification and design of third generation androgen receptor modulators are also described herein. Third generation androgen receptor modulatory regulators that inhibit the activity of modified androgen receptor polypeptides are described herein. Such androgen receptor modulators can be administered alone, in combination with other compounds and in combination with other compounds, to treat diseases or conditions including, but not limited to, pharmaceutical compositions and medicaments comprising the compounds described herein, and cancer, such as castration-resistant prostate cancer, And a method of using them in combination is also described. |